Search alternatives:
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
17521
-
17522
-
17523
-
17524
-
17525
-
17526
OGD in lG partly preserves Δψ<sub>m</sub> (i.e. delays depolarization) caused by subsequent NaN<sub>3</sub> treatment.
Published 2014“…Depolarization is visible in the normoxic group (b, c) (seen as concentration-dependent decrease in magenta and increase in blue color), but it is more pronounced than in OGD group after treatment with NaN<sub>3</sub> (e, f). …”
-
17527
-
17528
Effect of mutations on neutralization by antibodies elicited by 2x BNT162b2 vaccination, Delta breakthrough after 2x mRNA vaccination, or primary Delta infection.
Published 2022“…Points represent the geometric mean across cohorts (NT50s plotted in (A)). Error bars represent geometric standard deviation. …”
-
17529
-
17530
-
17531
-
17532
-
17533
-
17534
-
17535
-
17536
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip...
Published 2021“…The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising <i>in vitro</i> activity of <b>12a</b> (CM-444) with GI<sub>50</sub> of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. …”
-
17537
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip...
Published 2021“…The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising <i>in vitro</i> activity of <b>12a</b> (CM-444) with GI<sub>50</sub> of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. …”
-
17538
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip...
Published 2021“…The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising <i>in vitro</i> activity of <b>12a</b> (CM-444) with GI<sub>50</sub> of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. …”
-
17539
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip...
Published 2021“…The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising <i>in vitro</i> activity of <b>12a</b> (CM-444) with GI<sub>50</sub> of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. …”
-
17540